2023
Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study
Faridi K, Strom J, Kundi H, Butala N, Curtis J, Gao Q, Song Y, Zheng L, Tamez H, Shen C, Secemsky E, Yeh R. Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study. Journal Of The American Heart Association 2023, 12: e029588. PMID: 37449567, PMCID: PMC10382113, DOI: 10.1161/jaha.123.029588.Peer-Reviewed Original ResearchMeSH KeywordsAgedAspirinChild, PreschoolDrug Therapy, CombinationFrailtyHemorrhageHumansMedicarePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsTreatment OutcomeUnited StatesConceptsExtended duration dual antiplatelet therapyDuration dual antiplatelet therapyNet adverse clinical eventsDual antiplatelet therapyAdverse clinical eventsPercutaneous coronary interventionCoronary interventionClinical eventsNonfrail patientsAntiplatelet therapyFrail patientsClaims dataMonths of DAPTClaims-based indexYears of ageMajor bleedingCause mortalityMultivariable adjustmentOlder patientsDAPT studyResults PatientsBackground FrailtyMyocardial infarctionClinical trialsMedicare claims
2021
Comparing Baseline Data From Registries With Trials Evidence From the CathPCI Registry and DAPT Study
Butala NM, Faridi KF, Secemsky EA, Song Y, Curtis J, Gibson CM, Brindis R, Shen C, Yeh RW. Comparing Baseline Data From Registries With Trials Evidence From the CathPCI Registry and DAPT Study. JACC Cardiovascular Interventions 2021, 14: 1386-1388. PMID: 34167685, PMCID: PMC8800637, DOI: 10.1016/j.jcin.2021.03.065.Peer-Reviewed Original ResearchMeSH KeywordsDrug Therapy, CombinationHumansPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsRegistriesTreatment OutcomeLack of Guideline-Directed Medical Therapy in Patients Undergoing Endovascular Procedures for Critical Limb Ischemia
Llanos-Chea F, Jelani QU, Trejo-Paredes C, Curtis JP, Parzynski CS, Huang J, Faridi KF, Turner J, Smolderen KG, Mena-Hurtado C. Lack of Guideline-Directed Medical Therapy in Patients Undergoing Endovascular Procedures for Critical Limb Ischemia. Journal Of The American College Of Cardiology 2021, 77: 1374-1375. PMID: 33706882, DOI: 10.1016/j.jacc.2020.12.063.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsCohort StudiesEndovascular ProceduresFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIschemiaMaleMiddle AgedPeripheral Arterial DiseasePlatelet Aggregation InhibitorsComparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study
Faridi KF, Tamez H, Butala NM, Song Y, Shen C, Secemsky EA, Mauri L, Curtis JP, Strom JB, Yeh RW. Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study. Circulation Cardiovascular Quality And Outcomes 2021, 14: e006589. PMID: 33435731, PMCID: PMC7855905, DOI: 10.1161/circoutcomes.120.006589.Peer-Reviewed Original ResearchMeSH KeywordsAgedDrug Therapy, CombinationFemaleHumansMaleMedicareMyocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsStrokeTreatment OutcomeUnited StatesConceptsNegative predictive valuePositive predictive valueMyocardial infarctionPredictive valueDAPT studyClinical trialsAdjudicated eventsClaims dataNational Cardiovascular Data Registry CathPCI RegistryClinical events committeeTrial of patientsPercutaneous coronary interventionTrial end pointsKappa statisticsAdjudicated deathCathPCI RegistryCerebrovascular eventsCoronary interventionCumulative incidenceEvents committeeOutcome ascertainmentBilling claimsInpatient hospitalizationBleeding rateCardiovascular disease
2020
Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
Faridi KF, Tamez H, Strom JB, Song Y, Butala NM, Shen C, Secemsky EA, Mauri L, Curtis JP, Gibson CM, Yeh RW. Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Circulation 2020, 142: 306-308. PMID: 32687440, PMCID: PMC7374757, DOI: 10.1161/circulationaha.120.047729.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicDual Anti-Platelet TherapyHumansMedicarePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsThrombosisUnited StatesPatient and hospital characteristics associated with ticagrelor uptake in acute MI: An analysis of the Chest Pain–MI Registry
Rodwin BA, Lu D, Giaimo A, Annapureddy A, Daggubati R, Curtis J, Sciria CT, Wang TY, Desai NR. Patient and hospital characteristics associated with ticagrelor uptake in acute MI: An analysis of the Chest Pain–MI Registry. International Journal Of Cardiology 2020, 304: 14-20. PMID: 31980270, DOI: 10.1016/j.ijcard.2020.01.029.Peer-Reviewed Original ResearchMeSH KeywordsChest PainHospitalsHumansMyocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsRegistriesTicagrelorTreatment OutcomeConceptsChest Pain-MI RegistryAcute myocardial infarctionTicagrelor useHospital characteristicsACC/AHA guidelinesUse of ticagrelorUse of clopidogrelHealth system performanceAHA guidelinesAcute MIHighest quartileAMI patientsInhibitor clopidogrelMI patientsMyocardial infarctionMultivariable modelWhite racePrasugrelPatientsTicagrelorHospitalPrivate insuranceClopidogrelP2YRegistry
2017
Hospital Performance on Percutaneous Coronary Intervention Process and Outcomes Measures
Chui PW, Parzynski CS, Nallamothu BK, Masoudi FA, Krumholz HM, Curtis JP. Hospital Performance on Percutaneous Coronary Intervention Process and Outcomes Measures. Journal Of The American Heart Association 2017, 6: e004276. PMID: 28446493, PMCID: PMC5524055, DOI: 10.1161/jaha.116.004276.Peer-Reviewed Original ResearchMeSH KeywordsCardiac RehabilitationCoronary DiseaseCross-Sectional StudiesHealthcare DisparitiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMedicarePatient DischargePatient ReadmissionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsProcess Assessment, Health CareQuality ImprovementQuality Indicators, Health CareReferral and ConsultationRegistriesRisk FactorsTime FactorsTime-to-TreatmentTreatment OutcomeUnited StatesConceptsProcess measuresReadmission ratesOutcome measuresNational Cardiovascular Data Registry CathPCI RegistryHospital performancePercutaneous coronary interventionSpecific process measuresRisk-standardized mortalityPCI patientsCathPCI RegistryCoronary interventionHospital variationOutcome ratesHospital qualityPhysician ConsortiumMortalitySmall percentageWeak correlationAssociationIntervention processPatients
2016
Impact of Glycoprotein IIb/IIIa Inhibitors Use on Outcomes After Lower Extremity Endovascular Interventions From Nationwide Inpatient Sample (2006–2011)
Arora S, Panaich SS, Patel N, Patel NJ, Lahewala S, Thakkar B, Savani C, Jhamnani S, Singh V, Patel N, Patel S, Sonani R, Patel A, Tripathi B, Deshmukh A, Chothani A, Patel J, Bhatt P, Mohamad T, Remetz MS, Curtis JP, Attaran RR, Mena CI, Schreiber T, Grines C, Cleman M, Forrest JK, Badheka AO. Impact of Glycoprotein IIb/IIIa Inhibitors Use on Outcomes After Lower Extremity Endovascular Interventions From Nationwide Inpatient Sample (2006–2011). Catheterization And Cardiovascular Interventions 2016, 88: 605-616. PMID: 26914274, DOI: 10.1002/ccd.26452.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAmputation, SurgicalCross-Sectional StudiesDatabases, FactualDrug CostsEndovascular ProceduresFemaleHospital CostsHospital MortalityHumansLimb SalvageLogistic ModelsLower ExtremityMaleMiddle AgedMultivariate AnalysisOdds RatioPeripheral Arterial DiseasePlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPropensity ScoreRisk FactorsTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsGlycoprotein IIb/IIIa inhibitorsPeripheral endovascular interventionsHospital mortalityHospitalization costsEndovascular interventionGPI useAmputation rateUtilization Project Nationwide Inpatient Sample databaseTwo-level hierarchical multivariateIIb/IIIa inhibitorsNationwide Inpatient Sample databaseLower amputation ratesPaucity of dataHospital outcomesPostprocedural complicationsSecondary outcomesPropensity matchingStudy cohortHealthcare costsICD-9Multivariate analysisStudy outcomesSample databaseMortalityHierarchical multivariate
2015
Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR)®
Ghanbari H, Nallamothu BK, Wang Y, Curtis JP. Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR)®. Journal Of The American Heart Association 2015, 4: e001331. PMID: 25637345, PMCID: PMC4345865, DOI: 10.1161/jaha.114.001331.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAtrial FibrillationCoronary Artery DiseaseDefibrillators, ImplantableDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansIncidenceMaleMedicareMiddle AgedPatient DischargePlatelet Aggregation InhibitorsRegistriesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesWarfarinConceptsImplantable cardioverter defibrillator implantationCardioverter-defibrillator implantationCoronary artery diseaseMajor adverse cardiovascular eventsNational Cardiovascular Data RegistryAdverse cardiovascular eventsDevice-related complicationsAntithrombotic agentsDefibrillator implantationArtery diseaseAtrial fibrillationAntithrombotic therapyBleeding riskCardiovascular eventsThromboembolic eventsNational Cardiovascular Data Registry Implantable Cardioverter Defibrillator RegistryImplantable Cardioverter-Defibrillator RegistryHigh bleeding riskCombination of DAHospital dischargeICD implantationPrimary outcomeData registryPatientsFibrillation
2003
Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study
Curtis JP, Wang Y, Portnay EL, Masoudi FA, Havranek EP, Krumholz HM. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. The BMJ 2003, 327: 1322. PMID: 14656840, PMCID: PMC286319, DOI: 10.1136/bmj.327.7427.1322.Peer-Reviewed Original Research